Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dementia01:30

Dementia

482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
482
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

JAMA·2026
Same author

Features predicting data exclusion in imaging studies of Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Blood-based proteomic signature of amyloidosis: identification of novel regulators of amyloid load.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

No cognitive or psychological impact from returning research Alzheimer disease biomarkers: A delayed-start, noninferiority, randomized clinical trial.

medRxiv : the preprint server for health sciences·2026
Same author

Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study.

Lancet (London, England)·2026
Same author

Elevated functional magnetic resonance imaging activity in cognitively normal participants predicts future dementia.

Brain communications·2026

相关实验视频

Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K

技术与痴呆症 会议前会议

Hannah M Wilks1, Matthew S Welhaf2, Andrew J Aschenbrenner2

  • 1Washington University in St. Louis, St. Louis, MO, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
PubMed
概括

夜间睡眠障碍会影响老年人的第二天认知能力,特别是APOE ε4携带者. 智能手机评估揭示了微妙的睡眠认知联系,这对阿尔茨海默氏症至关重要.

更多相关视频

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

相关实验视频

Last Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

科学领域:

  • 老年学和认知神经科学
  • 睡眠科学和神经退行研究研究

背景情况:

  • 技术进步在日常生活中促进了自然主义的认知和睡眠评估.
  • 了解夜间睡眠对第二天认知的影响对于老年人患阿尔茨海默病 (AD) 风险至关重要.
  • 这项研究探讨了认知,睡眠,AD生物标志物和认知正常的老年人遗传风险之间的相互作用.

研究的目的:

  • 研究认知正常的老年人日常睡眠模式和第二天的认知表现之间的关联.
  • 检查遗传风险 (APOE ε4) 和AD生物标志物如何改变睡眠认知关系.
  • 为了利用基于智能手机的新方法进行高频,多天的评估.

主要方法:

  • 招募了344名没有认知障碍的老年人.
  • 利用门诊认知研究 (ARC) 智能手机应用程序,每天评估关联记忆,处理速度和空间工作记忆.
  • 收集每日关于睡眠满意度,警觉,时间,效率和持续时间的自我报告;计算睡眠健康复合和夜间偏差.
  • 采用线性和通用添加模型,控制年龄,性别,教育,APOE ε4状态和临床前AD生物标志物.

主要成果:

  • 与典型睡眠的夜间偏差显著与第二天认知能力的恶化有关 (p = 0.035).
  • 这种关联在APOE ε4载体中尤为明显 (p = 0.017),但在非载体中并非如此.
  • 每周的睡眠和认知没有显著的关联;临床前的AD生物标志物状态没有改变每日或每周的睡眠-认知关系.

结论:

  • 高频,多天评估显示,夜间睡眠质量微妙地影响了认知正常的老年人第二天的认知.
  • APOE ε4 载体对睡眠障碍对认知影响的敏感性增加.
  • 强调了多维睡眠和认知评估对阿尔茨海默病风险较高的老年人的重要性.